Sudarshan Pharma Industries Ltd
Incorporated in 2008, Sudarshan Pharma Industries Ltd manufactures API and Pharmaceutical Items. It also trades in Chemicals and Solvents[1]
- Market Cap ₹ 689 Cr.
- Current Price ₹ 28.6
- High / Low ₹ 53.5 / 22.3
- Stock P/E 34.9
- Book Value ₹ 5.82
- Dividend Yield 0.00 %
- ROCE 15.5 %
- ROE 14.8 %
- Face Value ₹ 1.00
Pros
- Company has delivered good profit growth of 69.7% CAGR over last 5 years
Cons
- Stock is trading at 4.93 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.5% over last 3 years.
- Debtor days have increased from 92.2 to 116 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 148 | 193 | 357 | 461 | 464 | 505 | 591 | |
| 143 | 186 | 346 | 446 | 441 | 465 | 547 | |
| Operating Profit | 5 | 7 | 11 | 15 | 23 | 40 | 44 |
| OPM % | 3% | 4% | 3% | 3% | 5% | 8% | 7% |
| 0 | 0 | 0 | 1 | 3 | -0 | 3 | |
| Interest | 3 | 3 | 3 | 5 | 9 | 16 | 20 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 2 | 3 |
| Profit before tax | 2 | 4 | 7 | 9 | 15 | 22 | 23 |
| Tax % | 26% | 25% | 26% | 26% | 25% | 26% | |
| 1 | 3 | 5 | 7 | 11 | 16 | 18 | |
| EPS in Rs | 0.13 | 0.28 | 0.54 | 0.29 | 0.48 | 0.66 | 0.77 |
| Dividend Payout % | 0% | 0% | 0% | 10% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 28% |
| 3 Years: | 12% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 70% |
| 3 Years: | 50% |
| TTM: | 57% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 13% |
| Last Year: | 15% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 10 | 24 | 24 | 24 | 24 |
| Reserves | 10 | 13 | 20 | 77 | 88 | 107 | 116 |
| 21 | 30 | 31 | 34 | 105 | 171 | 219 | |
| 18 | 47 | 77 | 97 | 67 | 100 | 148 | |
| Total Liabilities | 58 | 99 | 138 | 232 | 283 | 402 | 507 |
| 6 | 6 | 6 | 20 | 26 | 24 | 53 | |
| CWIP | 0 | 0 | 1 | 0 | 2 | 6 | 28 |
| Investments | 0 | 0 | 0 | 12 | 14 | 30 | 2 |
| 53 | 93 | 131 | 200 | 242 | 342 | 424 | |
| Total Assets | 58 | 99 | 138 | 232 | 283 | 402 | 507 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 1 | 3 | -4 | -29 | 8 | 35 | |
| -3 | -1 | -1 | -26 | -7 | -20 | |
| -0 | -1 | 4 | 66 | -12 | -14 | |
| Net Cash Flow | -2 | -0 | -1 | 11 | -12 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 66 | 114 | 75 | 64 | 96 | 116 |
| Inventory Days | 46 | 49 | 51 | 63 | 74 | 117 |
| Days Payable | 40 | 91 | 80 | 78 | 49 | 76 |
| Cash Conversion Cycle | 72 | 72 | 46 | 50 | 122 | 156 |
| Working Capital Days | 35 | 29 | 27 | 54 | 59 | 53 |
| ROCE % | 15% | 19% | 15% | 14% | 16% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
20 Oct - Copy of certificates received from Kfin Technologies Limited, Registrar & Share Transfer Agent under Regulation 74(5) of SEBI (Depository & Participants) Regulations, 2018 for the …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Oct - Newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30-September-2025 published in Mumbai Lakshdeep and Financial Express …
-
Announcement under Regulation 30 (LODR)-Change in Directorate
19 Oct - Independent Director Umesh Luthra resigns effective 18 Oct 2025 due to pre-occupation.
-
Financial Results For The Quarter And Half Year Ended 30-Sep-2025
18 Oct - Q2/H1 unaudited results approved; FCCB USD15m, fundraise up to Rs1,500Cr, Rs25.50Cr acquisition.
-
Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended 30-Sep-2025
15 Oct - Board meeting 18 Oct 2025 to approve audited results for quarter ended 30 Sep 2025; trading window closed.
Business Overview:[1][2]
SPIL does jobwork manufacturing in pharmaceutical Items and trading in chemicals and solvents in India. It
specializes in a host of products from rock chemicals intermediates and API to finish formulations and fully
integrated pharmaceutical and chemicals